| Name | Title | Contact Details |
|---|
ASK Childhood Cancer Foundation is a nonprofit organization that provides assistance, support, and kindness to families whose children are being treated for cancer in Central Virginia.
About J&K PMS, Inc., it's employees and company
MedAptus is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Carolina Pines Regional Medical Center, we "care for our own, right here at home." A leader in providing quality health care services to the people of several counties in northeastern South Carolina, patients have come to rely on our experienced, skilled staff and physicians to provide them with the highest level of care and compassion. Through the facilities on our campus, including a 116-bed acute care hospital and an adjoining medical office building, we provide comprehensive services with two things in mind: the care and comfort of our patients. From routine checkups to complex, state of the art surgery, Carolina Pines Regional Medical Center wants to be your health care provider of choice. Our goal is to be valued for our leadership, expertise and the ability to positively impact the quality of life for the citizens in our service area which includes Darlington, Chesterfield, Lee and Marlboro Counties. It is our privilege to care for our own, right here at home. This hospital is partially owned by physicians.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.